Howard Trachtman, MD, from NYU Langone Health, provides an overview of the safety and efficacy of sparsentan to treat focal segmental glomerulosclerosis (FSGS).

FSGS is a heterogeneous kidney disorder that often presents with a variable degree of proteinuria and nephrotic syndrome. 

Current treatment options can include corticosteroids or other immunomodulating agents aimed to reduce proteinuria but new treatments, such as sparsentan are in development. Sparsentan is a dual endothelin receptor and angiotensin receptor antagonist.

Dr. Trachtman led the phase 2 DUET study testing the ability of sparsetan to reduce proteinuria in patients with FSGS compared to irbesartan, an angiotensin receptor antagonists. That study, published in the Journal of the American Society of Nephrology, showed the drug to be safe and effective. A phase 3 study is currently underway. 

To learn more about this and other kidney disorders, visit